Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Withdrawn Phase 2 Interventional

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

ClinicalTrials.gov ID: NCT02321306

Public ClinicalTrials.gov record NCT02321306. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Open-label, multicenter study in adults with Primary Biliary Cirrhosis (PBC) designed to evaluate the long-term safety and tolerability of daily dosing with LUM001.

Study identification

NCT ID
NCT02321306
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 2
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2015
Primary completion
Nov 30, 2017
Completion
Feb 28, 2018
Last update posted
Mar 18, 2019

2015 – 2018

United States locations

U.S. sites
13
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Scripps Clinic La Jolla California 92037
University of California at Davis Sacramento California 95817
University of Miami Miami Florida 33136
Indiana University Indianapolis Indiana 46202
University of Louisville Louisville Kentucky 40202
Henry Ford Health System Detroit Michigan 48202
Minnesota Gastroenterology Saint Paul Minnesota 55114
St. Louis University St Louis Missouri 63104
Weill Cornell Medical College New York New York 10021
University of Texas Southwestern Medical Center Dallas Texas 75390
Liver Institute of Virginia Newport News Virginia 23602
Hunter Holmes McGuire VA Medical Center Richmond Virginia 23249
University of Washington Harborview Medical Center Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02321306, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 18, 2019 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02321306 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →